Combinatorial Auction Based Mechanism Design for Course Offering Determination

A. Vassiliev,F. Lin,M. A. Dewan

DOI: https://doi.org/10.1007/978-3-319-58463-8_32

2017-07-09

Interacción

Abstract:

What problem does this paper attempt to address?

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial

Avika Dixit,Richard Bennett,Kashif Ali,Carl Griffin,Robert A Clifford,Mark Turner,Rosanne Poston,Kelly Hautzinger,Anne Yeakey,Bethany Girard,Wen Zhou,Weiping Deng,Honghong Zhou,Sabine Schnyder Ghamloush,Barbara J Kuter,Karen Slobod,Jacqueline M Miller,Frances Priddy,Rituparna Das,ROVER Study Investigators,Kashif Ali,Madhavi Ampajwala,Andrew Atz,Richard Bennett,Gary Berman,Robert Clifford,Michael Dunn,Frank Eder,George Fuchs,Carl Griffin,John M. Hernandez,Robert Jeanfreau,Kimball Johnson,William Lavery,Jay Meyer,William Muller,Richard Ohnmacht,Amruta Padhye,Khozema Palanpurwala,Carina Rodrigue,Mark Turner,Todd Vasko,John Waits,Peter Warfield

DOI: https://doi.org/10.1016/s1473-3099(24)00101-4

IF: 71.421

2024-03-21

The Lancet Infectious Diseases

Abstract:Summary Background Variant-containing mRNA vaccines for COVID-19 to broaden protection against SARS-CoV-2 variants are recommended based on findings in adults. We report interim safety and immunogenicity of an omicron BA.1 variant-containing (mRNA-1273.214) primary vaccination series and booster dose in paediatric populations. Methods This open-label, two-part, non-randomised phase 3 trial enrolled participants aged 6 months to 5 years at 24 US study sites. Eligible participants were generally healthy or had stable chronic conditions, without known SARS-CoV-2 infection in the previous 90 days. Individuals who were acutely ill or febrile 1 day before or at the screening visit or those who previously received other COVID-19 vaccines (except mRNA-1273 for part 2) were excluded. In part 1, SARS-CoV-2-vaccine-naive participants received two-dose mRNA-1273.214 (25 μg; omicron BA.1 and ancestral Wuhan-Hu-1 mRNA) primary series. In part 2, participants who previously completed the two-dose mRNA-1273 (25 μg) primary series in KidCOVE ( NCT04796896 ) received a mRNA-1273.214 (10 μg) booster dose. Primary study outcomes were safety and reactogenicity of the mRNA-1273.214 primary series (part 1) or booster dose (part 2) as well as the inferred effectiveness of mRNA-1273.214 based on immune responses against ancestral SARS-CoV-2 (D614G) and omicron BA.1 variant at 28 days post-primary series (part 1) or post-booster dose (part 2). The safety set included participants who received at least one dose of the study vaccine; the immunogenicity set included those who provided immunogenicity samples. Interim safety and immunogenicity are summarised in this analysis as of the data cutoff date (Dec 5, 2022). This trial is registered with ClinicalTrials.gov , NCT05436834 . Findings Between June 21, 2022, and Dec 5, 2022, 179 participants received one or more doses of mRNA-1273.214 primary series (part 1) and 539 received a mRNA-1273.214 booster dose (part 2). The safety profile within 28 days after either dose of the mRNA-1273.214 primary series and the booster dose was consistent with that of the mRNA-1273 primary series in this age group, with no new safety concerns or vaccine-related serious adverse events observed. At 28 days after primary series dose 2 and the booster dose, both mRNA-1273.214 primary series (day 57, including all participants with or without evidence of prior SARS-CoV-2 infection at baseline) and booster (day 29, including participants without evidence of prior SARS-CoV-2 infection at baseline) elicited responses that were superior against omicron-BA.1 (geometric mean ratio part 1: 25·4 [95% CI 20·1–32·1] and part 2: 12·5 [11·0–14·3]) and non-inferior against D614G (part 1: 0·8 [0·7–1·0] and part 2: 3·1 [2·8–3·5]), compared with neutralising antibody responses induced by the mRNA-1273 primary series (in a historical comparator group). Interpretation mRNA-1273.214 was immunogenic against BA.1 and D614G in children aged 6 months to 5 years, with a comparable safety profile to mRNA-1273, when given as a two-dose primary series or a booster dose. These results are aligned with the US Centers for Disease Control and Prevention recommendations for the use of variant-containing vaccines for continued protection against the emerging variants of SARS-CoV-2. Funding Moderna.

infectious diseases
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Dean Follmann,Gregory Hachigian,Cynthia Strout,J. Scott Overcash,Susanne Doblecki-Lewis,Jennifer A. Whitaker,Evan J. Anderson,Kathleen Neuzil,Lawrence Corey,Frances Priddy,Joanne E. Tomassini,Mollie Brown,Bethany Girard,Dina Stolman,Veronica Urdaneta,Xiaowei Wang,Weiping Deng,Honghong Zhou,Avika Dixit,Rituparna Das,Jacqueline M. Miller,

DOI: https://doi.org/10.1038/s41467-024-50376-z

IF: 16.6

2024-08-29

Nature Communications

Abstract:Abstract Primary vaccination with mRNA-1273 (100-μg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across 99 U.S. sites. The open-label (Parts B and C) primary objectives were evaluation of long-term safety and effectiveness of primary vaccination plus a 50-μg booster dose; immunogenicity was a secondary objective. Of 29,035 open-label participants, 19,609 received boosters (mRNA-1273 [ n = 9647]; placebo-mRNA-1273 [ n = 9952]; placebo [ n = 10] groups). Booster safety was consistent with that reported for primary vaccination. Incidences of COVID-19 and severe COVID-19 were higher during the Omicron BA.1 than Delta variant waves and boosting versus non-boosting was associated with a significant, 47.0% (95% CI : 39.0-53.9%) reduction of Omicron BA.1 incidence (24.6 [23.4 − 25.8] vs 46.4 [40.6 − 52.7]/1000 person-months). In an exploratory Cox regression model adjusted for time-varying covariates, a longer median interval between primary vaccination and boosting (mRNA-1273 [13 months] vs placebo-mRNA-1273 [8 months]) was associated with significantly lower, COVID-19 risk (24.0% [16.0% − 32.0%]) during Omicron BA.1 predominance. Boosting elicited greater immune responses against SARS-CoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with mRNA-1273 demonstrated acceptable safety, effectiveness and immunogenicity against COVID-19, including emergent variants.

multidisciplinary sciences
The activity and toxicity of ampules amytal sodium and seconal sodium in aqueous polyethylene glycol 200.

E. E. Swanson,R. Anderson,P. N. Harris,C. L. Rose

DOI: https://doi.org/10.1002/JPS.3030420914

1953-09-01

Abstract:
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Angela Choi,Matthew Koch,Kai Wu,Laurence Chu,LingZhi Ma,Anna Hill,Naveen Nunna,Wenmei Huang,Judy Oestreicher,Tonya Colpitts,Hamilton Bennett,Holly Legault,Yamuna Paila,Biliana Nestorova,Baoyu Ding,David Montefiori,Rolando Pajon,Jacqueline M. Miller,Brett Leav,Andrea Carfi,Roderick McPhee,Darin K. Edwards

DOI: https://doi.org/10.1038/s41591-021-01527-y

IF: 82.9

2021-09-15

Nature Medicine

Abstract:Abstract The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study ( NCT04405076 ) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups ( n = 20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned ( P < 0.0001) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated. All boosters, including mRNA-1273, numerically increased neutralization titers against the wild-type D614G virus compared to peak titers against wild-type D614G measured 1 month after the primary series; significant increases were observed for mRNA-1273 and mRNA-1273.211 ( P < 0.0001). In addition, all boosters increased neutralization titers against key VOCs and VOIs, including B.1.351, P.1. and B.1.617.2, that were statistically equivalent to peak titers measured after the primary vaccine series against wild-type D614G virus, with superior titers against some VOIs. This trial is ongoing.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Immunogenicity, clinical efficacy and safety of additional second COVID‐19 booster vaccines against Omicron and its subvariants: A systematic review

Santenna Chenchula,Madhu Bhargavi Chandra,Madhu Babu Adusumilli,Sai Nikhila Ghanta,Anusha Bommasani,Anitha Kuttiappan,R. Padmavathi,Krishna Chaitanya Amerneni,Radhika Chikatipalli,Mohan Krishna Ghanta,Samarra Simha Reddy,K. Mythili Bai,Satya Prakash,G. Jogender,Madhavrao Chavan,S. Balakrishnan

DOI: https://doi.org/10.1002/rmv.2515

2024-01-25

Reviews in Medical Virology

Abstract:The Omicron variant of severe acute respiratory syndrome coronavirus 2 is a new variant of concern (VOC) and an emerging subvariant that exhibits heightened infectivity, transmissibility, and immune evasion, escalating the incidence of moderate to severe coronavirus disease 2019 (COVID‐19). It resists monoclonal antibodies and diminishes vaccine efficacy. Notably, new sublineages have outpaced earlier predominant sublineages. Although the primary vaccination series and initial boosters were robust against previous VOCs, their efficacy waned against Omicron and its subvariants. In this systematic review, we assessed real‐world evidence on the immunogenicity, clinical efficacy, and safety of a second booster or fourth COVID‐19 vaccine dose against the Omicron VOC and its subvariants. A comprehensive literature search was conducted in Medline/PubMed, Google Scholar, bioRxiv, and medRxiv, and relevant studies published between 2022 and 30 May 2023 were reviewed. We found a total of 40 relevant articles focusing on a second booster dose for COVID‐19, including clinical trials and observational studies, involving 3,972,856 patients. The results consistently revealed that an additional second booster dose restored and prolonged waning immunity, activating both humoral and cellular responses against Omicron and its subvariants. A second booster treatment correlated with enduring protection against COVID‐19, notably preventing substantial symptomatic disease and mortality associated with severe Omicron infection. Both monovalent messenger RNA (mRNA) and nonmRNA vaccines demonstrated similar efficacy and safety, with bivalent mRNA vaccines exhibiting broader protection against emerging subvariants of Omicron. The safety profiles of second booster were favourable with only mild systemic and local symptoms reported in some recipients. In conclusion, this systematic review underscores the additional COVID‐19 vaccine boosters, particularly with bivalent or multivalent mRNA vaccines, for countering the highly infectious emerging subvariants of Omicron.

virology
Indications for surgical intervention in middle cerebral artery obstruction.

A. Day

DOI: https://doi.org/10.3171/JNS.1984.60.2.0296

IF: 5.408

1984-02-01

Journal of Neurosurgery

Abstract:The clinical, angiographic, and surgical characteristics of 31 patients with high-grade middle cerebral artery (MCA) stenosis or occlusion (jointly termed "MCA obstructions") referred for cerebral revascularization by extracranial-intracranial (EC-IC) bypass are reviewed. Overall, 12 (66%) of the 18 patients with stenosis and all 13 (100%) of those with complete occlusion experienced clinically evident infarctions. Twenty-five of these patients underwent arteriography at least twice during their clinical course. Eleven (44%) demonstrated significant improvement in flow or complete resolution of obstruction on their second study. Ten of these 11 were patients in whom the initial arteriography was done within 2 weeks of symptom onset. Five other patients with stenosis exhibited obstruction that was worse on serial arteriography without surgical intervention. The high incidence of resolution of MCA obstructions indicates that surgery should not be contemplated in most instances until delayed arteriography has been performed, at least 6 weeks after the onset of symptoms. Proximal embolic sources, such as the cervical carotid bifurcation, should receive carotid endarterectomy and repeat arteriography in appropriate patients prior to consideration of EC-IC bypass. Persistent high-grade MCA obstructions are thereafter potential candidates for EC-IC bypass, since leptomeningeal collateral vessels are marginal in their protective ability. Overall, of 15 patients who underwent an EC-IC bypass procedure, 14 were either stable or improved postoperatively, and 13 have been free of any further ischemic events without the use of major anticoagulant agents.
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

Xuan Ying Poh,Chee Wah Tan,Jean-Marc Chavatte,Siew-Wai Fong,Tessa Prince,Catherine Hartley,Suma Rao,Po Ying Chia,Tau Hong Lee,Clarissa Lim,Jefanie Teo,Wanni Chia,Ee Chee Ren,Laurent Renia,David Chien Lye,Lin-Fa Wang,Barnaby E Young,I Russel Lee,Aileen Y Y Yeoh,Sean W X Ong,Sapna P Sadarangani,Ray J H Lin,Daniel R X Lim,Julian A Hiscox,Lisa F P Ng,Raymond T P Lin

DOI: https://doi.org/10.1093/cid/ciac345

IF: 20.999

2022-05-11

Clinical Infectious Diseases

Abstract:Abstract Background Waning antibody levels post-vaccination and the emergence of variants of concern (VOCs) capable of evading protective immunity have raised the need for booster vaccinations. However, which combination of coronavirus disease 2019 (COVID-19) vaccines offers the strongest immune response against the Omicron variant is unknown. Methods This randomized, participant-blinded, controlled trial assessed the reactogenicity and immunogenicity of different COVID-19 vaccine booster combinations. A total of 100 BNT162b2-vaccinated individuals were enrolled and randomized 1:1 to either homologous (BNT162b2 + BNT162b2 + BNT162b2; “BBB”) or heterologous messenger RNA (mRNA) (BNT162b2 + BNT162b2 + mRNA-1273; “BBM”) booster vaccine. The primary end point was the level of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type and VOCs at day 28. Results A total of 51 participants were allocated to BBB and 49 to BBM; 50 and 48, respectively, were analyzed for safety and immunogenicity outcomes. At day 28 post-boost, mean SARS-CoV-2 spike antibody titers were lower with BBB (22 382 IU/mL; 95% confidence interval [CI], 18 210 to 27 517) vs BBM (29 751 IU/mL; 95% CI, 25 281 to 35 011; P = .034) as was the median level of neutralizing antibodies: BBB 99.0% (interquartile range [IQR], 97.9% to 99.3%) vs BBM 99.3% (IQR, 98.8% to 99.5%; P = .021). On subgroup analysis, significant higher mean spike antibody titer, median surrogate neutralizing antibody level against all VOCs, and live Omicron neutralization titer were observed only in older adults receiving BBM. Both vaccines were well tolerated. Conclusions Heterologous mRNA-1273 booster vaccination compared with homologous BNT123b2 induced a stronger neutralizing response against the Omicron variant in older individuals. Clinical Trials Registration NCT05142319.

immunology,infectious diseases,microbiology
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial

Amparo L Figueroa,Dania Torres,Celia Reyes-Acuna,Paul Matherne,Anne Yeakey,Weiping Deng,Wenqin Xu,Yelena Sigal,Greer Chambers,Michelle Olsen,Bethany Girard,Jacqueline M Miller,Rituparna Das,Frances Priddy

DOI: https://doi.org/10.1016/S1473-3099(24)00501-2

2024-09-24

Abstract:Background: Most individuals show immunity to SARS-CoV-2 from vaccination or infection, or both. We aimed to determine the safety and immunogenicity of an omicron-containing COVID-19 vaccine (mRNA-1273.222) in vaccine-naive adolescents who were SARS-CoV-2 positive. Methods: Part 3 of the phase 2/3 TeenCOVE trial was a phase 3, open-label, single-arm part done in the USA and the Dominican Republic that enrolled healthy, vaccine-naive adolescents (aged 12-17 years) to receive two 50 μg doses of mRNA-1273.222 (ancestral strain Wuhan-Hu-1 and omicron subvariants BA.4 and BA.5), 6 months apart. Primary reactogenicity and safety outcomes included assessment of solicited local or systemic adverse reactions 7 days after vaccination, and unsolicited and prespecified adverse events throughout study participation. Inferred effectiveness (primary immunogenicity outcome) was established by comparing neutralising antibody responses 28 days after dose 1 of mRNA-1273.222 in SARS-CoV-2-positive adolescents with responses 28 days after dose 2 of mRNA-1273 100 μg primary series in SARS-CoV-2-negative young adults (aged 18-25 years) from the COVE trial. This study is registered with ClinicalTrials.gov (NCT04649151). Findings: Between Dec 21, 2022, and June 5, 2023, 379 adolescents (378 of whom were SARS-CoV-2 positive) received at least one mRNA-1273.222 dose and were included in the safety analysis set. The reactogenicity profile was favourable compared with the mRNA-1273 primary series, with no new safety concerns identified. Unsolicited adverse events were reported in 49 (13%) of 379 participants; no deaths or adverse events leading to study discontinuation were reported. The immunogenicity set included 245 adolescents from the per-protocol immunogenicity subset who were SARS-CoV-2 positive at baseline and 296 young adults who were SARS-CoV-2 negative. Compared with the mRNA-1273 primary series in SARS-CoV-2-negative young adults, a single dose of mRNA-1273.222 induced superior (geometric mean ratio [GMR] 95% CI lower bound >1) neutralising antibody responses against omicron BA.4 and BA.5 (GMR 48·95 [95% CI 44·21-54·21]) and non-inferior (GMR 95% CI lower bound >0·667) neutralising antibody responses against ancestral SARS-CoV-2 (GMR 4·25 [95% CI 3·69-4·88]) in SARS-CoV-2-positive adolescents. Interpretation: In vaccine-naive, SARS-CoV-2-positive adolescents, single-dose mRNA-1273.222 was effective against COVID-19 based on successful immunobridging to the two-dose mRNA-1273 primary series in young adults. The findings support a simplified single-dose vaccination schedule with variant-containing mRNA vaccines, regardless of previous vaccination status. Funding: Moderna.
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Astrid K. Hvidt,Eva A. M. Baerends,Ole S. Søgaard,Nina B. Stærke,Dorthe Raben,Joanne Reekie,Henrik Nielsen,Isik S. Johansen,Lothar Wiese,Thomas L. Benfield,Kasper K. Iversen,Ahmed B. Mustafa,Maria R. Juhl,Kristine T. Petersen,Sisse R. Ostrowski,Susan O. Lindvig,Line D. Rasmussen,Marianne H. Schleimann,Sidsel D. Andersen,Anna K. Juhl,Lisa L. Dietz,Signe R. Andreasen,Jens Lundgren,Lars Østergaard,Martin Tolstrup,

DOI: https://doi.org/10.3389/fmed.2022.994160

IF: 3.9

2022-10-03

Frontiers in Medicine

Abstract:The SARS-CoV-2 pandemic has, as of July 2022, infected more than 550 million people and caused over 6 million deaths across the world. COVID-19 vaccines were quickly developed to protect against severe disease, hospitalization and death. In the present study, we performed a direct comparative analysis of four COVID-19 vaccines: BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), ChAdOx1 (Oxford/AstraZeneca) and Ad26.COV2.S (Johnson & Johnson/Janssen), following primary and booster vaccination. We focused on the vaccine-induced antibody-mediated immune response against multiple SARS-CoV-2 variants: wildtype, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and B.1.1.529 (Omicron). The analysis included the quantification of total IgG levels against SARS-CoV-2 Spike, as well as the quantification of antibody neutralization titers. Furthermore, the study assessed the high-throughput ACE2 competition assay as a surrogate for the traditional pseudovirus neutralization assay. The results demonstrated marked differences in antibody-mediated immune responses. The lowest Spike-specific IgG levels and antibody neutralization titers were induced by one dose of the Ad26.COV2.S vaccine, intermediate levels by two doses of the BNT162b2 vaccine, and the highest levels by two doses of the mRNA-1273 vaccine or heterologous vaccination of one dose of the ChAdOx1 vaccine and a subsequent mRNA vaccine. The study also demonstrated that accumulation of SARS-CoV-2 Spike protein mutations was accompanied by a marked decline in antibody neutralization capacity, especially for B.1.1.529. Administration of a booster dose was shown to significantly increase Spike-specific IgG levels and antibody neutralization titers, erasing the differences between the vaccine-induced antibody-mediated immune response between the four vaccines. The findings of this study highlight the importance of booster vaccines and the potential inclusion of future heterologous vaccination strategies for broad protection against current and emerging SARS-CoV-2 variants.

medicine, general & internal
Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Tseng,H. F.,Ackerson,B. K.,Bruxvoort,K. J.,Sy,L. S.,Tubert,J. E.,Lee,G. S.,Ku,J. H.,Florea,A.,Luo,Y.,Qiu,S.,Choi,S. K.,Takhar,H. S.,Aragones,M.,Paila,Y. D.,Chavers,S.,Qian,L.

DOI: https://doi.org/10.1101/2022.09.30.22280573

2022-10-02

MedRxiv

Abstract:Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against Omicron BA.4/BA.5 compared with earlier Omicron subvariants. We conducted a test-negative case-control study evaluating mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron subvariants. The study included 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged [≥]18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection was high and waned slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection was initially moderate to high (61.0%-90.6% 14-30 days post third dose) and waned rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranged between 64.3%-75.7%, and was low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 was 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 was 88.5%. Evaluation of the updated bivalent booster is warranted.
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

Rontgene Solante,Carlos Alvarez-Moreno,Erlina Burhan,Suwat Chariyalertsak,Nan-Chang Chiu,Sunate Chuenkitmongkol,D V Dung,Kao-Pin Hwang,Javier Ortiz Ibarra,Sasisopin Kiertiburanakul,Prasad S Kulkarni,Christopher Lee,Ping-Ing Lee,Rommel Crisenio Lobo,Alejandro Macias,Cao Huu Nghia,Anna Lisa Ong-Lim,Alfonso J Rodriguez-Morales,Rosana Richtmann,Marco Aurélio Palazzi Safadi,Hindra Irawan Satari,Guy Thwaites

DOI: https://doi.org/10.1080/14760584.2023.2143347

Abstract:Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Areas covered: Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Expert opinion: Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.
Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines

Spyros Chalkias,Nichole McGhee,Jordan L Whatley,Brandon Essink,Adam Brosz,Joanne E Tomassini,Bethany Girard,Darin K Edwards,Kai Wu,Arshan Nasir,Diana Lee,Laura E Avena,Jing Feng,Weiping Deng,David C Montefiori,Lindsey R Baden,Jacqueline M Miller,Rituparna Das

DOI: https://doi.org/10.1093/infdis/jiae067

2024-02-14

The Journal of Infectious Diseases

Abstract:Background Monovalent Omicron XBB.1.5-containing vaccines were approved for Coronavirus disease 2019 (COVID-19) 2023-2024 immunizations. Methods This ongoing, open-label, phase 2/3 study evaluated mRNA-1273.815-monovalent (50-μg Omicron XBB.1.5-spike mRNA) and mRNA-1273.231-bivalent (25-μg each Omicron XBB.1.5- and BA.4/BA.5-spike mRNAs))vaccines, administered as 5th doses to adults who previously received a primary series, a 3rd dose of an original mRNA COVID-19 vaccine, and a 4th dose of an Omicron BA.4/BA.5 bivalent vaccine. Interim safety and immunogenicity results 29 days post-vaccination are reported. Results Participants (randomized 1:1) received 50-μg mRNA-1273.815(n=50) or mRNA-1273.231(n=51); median (interquartile range) months from the prior BA.4/BA.5-bivalent dose were 8.2 (8.1-8.3) and 8.3 (8.1-8.4), respectively. Neutralizing antibody (nAb) increased from pre-booster levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants tested. Day 29 nAb fold-increases from pre-booster levels were numerically higher against XBB.1.5, XBB.1.16, EG.5.1, BA.2.86, and JN.1 than BA.4/BA.5, BQ.1.1 and D614G. The monovalent vaccine also cross-neutralized FL.1.5.1, EG.5.1, BA.2.86, HK.3.1, HV.1 and JN.1 variants in a participant (n=20) subset, 15 days post-vaccination. Reactogenicity was similar to previously reported mRNA-1273 original and bivalent vaccines. Conclusions XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants including JN.1, supporting the XBB.1.5-spike sequence selection for the 2023-2024 COVID-19 vaccine update.

immunology,infectious diseases,microbiology
Getting men to talk about suicide.

L. Moxham,Christopher Patterson

2015-11-01

Abstract:It may be hard to get men talking about their mental health, but that is just what we need to do. Disciplines Medicine and Health Sciences | Social and Behavioral Sciences Publication Details Moxham, L. & Patterson, C. (2015). Getting men to talk about suicide. Australian Nursing and Midwifery Journal, 23 (5), 39-39. This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/3338 Getting men to talk about suicide By Lorna Moxham and Christopher Patterson
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Hung Fu Tseng,Bradley K. Ackerson,Katia J. Bruxvoort,Lina S. Sy,Julia E. Tubert,Gina S. Lee,Jennifer H. Ku,Ana Florea,Yi Luo,Sijia Qiu,Soon Kyu Choi,Harpreet S. Takhar,Michael Aragones,Yamuna D. Paila,Scott Chavers,Carla A. Talarico,Lei Qian

DOI: https://doi.org/10.1038/s41467-023-35815-7

IF: 16.6

2023-01-12

Nature Communications

Abstract:Abstract Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against omicron BA.4/BA.5 compared with earlier omicron subvariants. This test-negative case–control study evaluates mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with omicron subvariants. The study includes 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection is high and wanes slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection is initially moderate to high (61.0%-90.6% 14-30 days post third dose) and wanes rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranges between 64.3%-75.7%, and is low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 is 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 is 88.5%. Evaluation of the updated bivalent booster is warranted.

multidisciplinary sciences
mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines

Biyan Zhang,Jianxin Huo,Yuhan Huang,Shuan Yong Teo,Kaibo Duan,Yanfeng Li,Lim Kai Toh,Kong Peng Lam,Shengli Xu

DOI: https://doi.org/10.3390/vaccines10071057

2022-07-01

Vaccines

Abstract:The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in different countries, and individuals who had adverse reactions to certain vaccine types require heterologous vaccine boosters. To understand the efficacy of different vaccination regimens in inducing humoral responses to SARS-CoV2, we examined plasma antibodies and frequencies of Omicron RBD-specific B cells in individuals who had different priming-booster vaccination regimens. We found that individuals with three homologous doses of mRNA vaccines had higher levels of IgG of all subclasses against RBD of Omicron than individuals with three homologous doses of inactivated virus vaccine. A booster with mRNA vaccine resulted in significant increases in median levels of RBD-reactive IgG1 (17–19 fold) and IgG3 (2.3–3.3 fold) as compared to individuals receiving inactivated virus booster shots regardless of priming vaccine types. More importantly, individuals who received a booster dose of mRNA vaccine, irrespective of the priming vaccine, had antibodies with higher neutralizing capability against the Omicron variant than those who received a booster dose of inactivated virus vaccine. Corroborating the antibody results, boosting with the mRNA vaccine increased the frequencies of Omicron RBD-binding B cells by (1.5–3.3 fold) regardless of priming vaccine types. Together, our data demonstrate that an mRNA vaccine (BNT162b2 or mRNA-1273) booster enhances humoral responses against the Omicron variant in individuals vaccinated with either two prior doses of mRNA or inactivated virus vaccine (CoronaVac or BBIBP-CorV), potentially providing more effective protection against SARS-CoV-2 infection, particularly by the Omicron variant.

immunology,medicine, research & experimental
Single equivalent dipole inverse electrocardiography based on ordinary 12 leads recordings

A. Saliakoura,G. Theodosiadou,A. Rigas,G. Kyriacou,M. Zervakis

DOI: https://doi.org/10.1109/PACET.2017.8259962

2017-11-01

Abstract:The characterization of cardiac electric activity by equivalent electric sources including dipoles received a great research effort in the past. Recently these methods are revisited but exploiting a grid of multiple electrodes (up to 200), but these multi-lead electrodes are not widespread yet. Certainly, most hospitals and ordinary cardiology practice is still based on standard 12-lead ECG recordings. Exactly towards this aim is the effort put herein, hardly to exploit standard 12-lead ECG recordings to extract an equivalent electric dipole for the cardiac activity. Ultimately, this work aims at a trustworthy and very fast inverse ECG algorithm able to operate even with a simple standard ECG device available on an ambulance. This could contribute to early diagnosis as the type of heart malfunctioning during the patient transfer to the hospital.
Safety and Immunogenicity of an mRNA-1273 Booster in Children

Vladimir Berthaud,C Buddy Creech,Christina A Rostad,Quito Carr,Liberation De Leon,Monika Dietrich,Anil Gupta,David Javita,Sharon Nachman,Swetha Pinninti,Mobeen Rathore,Carina A Rodriguez,Katherine Luzuriaga,William Towner,Anne Yeakey,Mollie Brown,Xiaoping Zhao,Weiping Deng,Wenqin Xu,Honghong Zhou,Bethany Girard,Roxanne Kelly,Karen Slobod,Evan J Anderson,Rituparna Das,Jacqueline Miller,Sabine Schnyder Ghamloush,on behalf the KidCOVE Study Group,Madhavi Ampajwala,Carey Chronis,Oscar De Valle,Elizabeth Reyes,Ronald Blair,Nathan G Forbush,Richard K Ohnmacht,Michael A Rausch,Jorge G Sainz,Robert A Clifford,Michael M Pfeffer,James D Campbell,James D Campbell,Andrew Atz,Sreedhar Chava,Mobeen Rathore,Michael Dunn,Kimball A Johnson,Daniel J Leonard,Arin Piramzadian,Konda M Reddy,Richard L Bennett,Quito Carr,Christelle Ilboudo,Andrew Siesennop,Ivan Melendez,Vladimir Berthaud,Michael Bolton,Walter J Rok,Randall Reese,Carina A Rodriguez,Monika Dietrich,George J Fuchs,Richard H Leggett,Shane McAllister,Rambod Rouhbakhsh,Inci Yildirim,Carl P Griffin,Wayne Shreffler,Keith Vrbicky,Frank S Eder,Liberation B De Leon,Paul K Pickrell,Michael W Simon,Robert Jeanfreau,Soren Gantt,Sergio Fanella,Charles Hui,Scott Halperin,James D Kellner,Manish Sadarangani,Sean (Ari) Bitnun

DOI: https://doi.org/10.1093/cid/ciae420

IF: 20.999

2024-08-21

Clinical Infectious Diseases

Abstract:A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25-μg) and 6-11 years (50-μg) had an acceptable safety profile and was immunogenic in the phase 2/3 KidCOVE study. We present data from KidCOVE participants who received an mRNA-1273 booster dose. An mRNA-1273 booster dose (10-μg for children aged 6 months-5 years; 25-μg for children aged 6-11 years; age groups based on participant age at enrollment) was administered ≥6 months after primary series completion. The primary safety objective was the safety and reactogenicity of an mRNA-1273 booster dose. The primary immunogenicity objective was to infer efficacy of an mRNA-1273 booster dose by establishing noninferiority of neutralizing antibody (nAb) responses after a booster in children compared with nAb responses observed after the mRNA-1273 primary series in young adults (18-25 years) from the pivotal efficacy study. Data were collected from March 2022 to June 2023. Overall, 153 (6 months-5 years) and 2519 (6-11 years) participants received an mRNA-1273 booster dose (median age at receipt of booster: 2 and 10 years, respectively). The booster dose safety profile was generally consistent with that of the primary series in children; no new safety concerns were identified. An mRNA-1273 booster dose elicited robust nAb responses against ancestral SARS-CoV-2 among children and met prespecified noninferiority success criteria when compared with responses observed after the primary series in young adults. Safety and immunogenicity data support administration of a mRNA-1273 booster dose in children aged 6 months to 11 years. NCT04796896

immunology,infectious diseases,microbiology
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice

Sue Ann Costa Clemens,Lily Weckx,Eveline P. Milan,Igor Smolenov,Ralf Clemens

DOI: https://doi.org/10.1016/j.vaccine.2024.05.009

IF: 4.169

2024-05-19

Vaccine

Abstract:Background The COVID-19 pandemic is over but the highly immunized or naturally exposed global population still requires booster vaccinations against newly emerging SARS-CoV-2 variants. We assessed safety and immunogenicity of booster doses of COVID-19 vaccines based on three different platforms in a setting that mimics the current routine practice in Brazil. Methods In this phase 3 study from 14 February 2023 to 12 June 2023 we enrolled previously immunized adults to receive an additional booster dose of one of three vaccines. Immunogenicity against ancestor SARS-CoV-2 and Omicron BF.7, BQ.1.1.3, and XBB.1.5.6 sub-lineages was measured as ELISA IgG or virus neutralizing (VNT) antibodies and safety/reactogenicity assessed using diary cards. Results Volunteers with a history of full primary COVID-19 immunization striated to three cohorts according to their previous booster vaccination history—0 (n = 26), 1 (n = 140) or 2 (n = 606) booster vaccinations—were randomized 2:1:1 to receive either recombinant protein (SCB-2019, Clover), adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz), or mRNA (BNT162b2, Pfizer/Wyeth). Baseline antibody titers were higher in individuals who had received one or two boosters and titers against both ancestor and Omicron sub-lineages increased in all groups regardless of the number of previous booster doses or the vaccine used. Day 28 geometric mean titers (GMTs) and geometric mean-fold rises (GMFR) against all variants were higher after BNT162b than SCB-2019 or ChAdOx1-S, but BNT162b groups displayed more rapid antibody waning at Day 84. Within cohorts each vaccine elicited similar GMFR against the different SARS-CoV-2 strains. All vaccines were well tolerated with similar solicited reactogenicity profiles. Conclusions Protein, adenovirus-vector or mRNA vaccine boosters were equally well tolerated and immunogenic against ancestor SARS-CoV-2 and Omicron sub-lineages in fully primed adults with 0–2 prior boosters. BNT162b induced the highest immune responses but also the most rapid waning of antibodies 3 months after vaccination. Clinical Trial Registration: ClinicalTrials.gov , identifier NCT05812586.

immunology,medicine, research & experimental
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

de Bruyn,G.,Wang,J.,Purvis,A.,Sanchez Ruiz,M.,Adhikarla,H.,Alvi,S.,Bonaparte,M. I.,Brune,D.,Bueso,A.,Canter,R. M.,Angeles Ceregido,M.,Diemert,D.,Finn,A.,Forrat,R.,Fu,B.,Gallais,J.,Griffin,P.,Grillet,M.-H.,Haney,O.,Henderson,J. A.,Koutsoukos,M.,Launay,O.,Martinon Torres,F.,Masotti,R.,Michael,N. L.,Park,J.,Rivera,D. M.,Romanyak,N.,Rook,C.,Schuerman,L.,Sher,L. D.,Tavares-Da-Silva Sachin Deshmukh,F.,Whittington,A.,Chicz,R. M.,Gurunathan,S.,Savarino,S.,Sridhar,S.,VAT00002 booster cohorts study team

DOI: https://doi.org/10.1101/2022.12.02.22282931

2022-12-04

MedRxiv

Abstract:Background Booster vaccines providing protection against emergent SARS-CoV-2 variants are needed. In an international phase 3 study, we evaluated booster vaccines containing prototype (D614) and/or Beta (B.1.351) variant recombinant spike proteins and AS03 adjuvant (CoV2 preS dTM-AS03). Methods Adults, primed 4-10 months earlier with mRNA (BNT162b2, mRNA-1273]), adenovirus-vectored (Ad26.CoV2.S, ChAdOx1nCoV-19) or adjuvanted protein (CoV2 preS dTM-AS03 [D614]) vaccines and stratified by age (18-55 and [≥]56 years), were boosted with monovalent (MV) D614 (5[≥]g, n=1285), MV (B.1351) (5g, n=707) or bivalent (BiV) (2.5[≥]g D614 plus 2.5[≥]g B.1.351, n=625) CoV2 preS dTM-AS03. SARS-CoV-2-naive adults (controls, n=479) received a primary series (two injections, 21 days apart) of CoV2 preS dTM-AS03 containing 10g D614. Antibodies to D614G, B.1.351 and Omicron BA.2 and BA.1 variants were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN) assay. D614G or B.1.351 PsVN titers 14 days (D15) post-booster were compared with pre-booster (D1) titers in BNT162b2-primed participants (18-55 years old) and controls (D36), for each booster formulation (co-primary objectives). Safety was evaluated throughout the trial. Results of a planned interim analysis are presented. Results Among BNT162b2-primed adults (18-55 years old), PsVN titers against D614G or B.1.351 were significantly higher post-booster than anti-D614G titers post-primary vaccination in controls, for all booster formulations, with an anti-D614G GMT ratio (98.3% CI) of 2.16 (1.69; 2.75) for MV(D614), an anti-B.1.351 ratio of 1.96 (1.54; 2.50) for MV (B.1.351) and anti-D614G and anti-B.1.351 ratios of 2.34 (1.84; 2.96) and 1.39 (1.09; 1.77), respectively, for BiV. All booster formulations elicited cross-neutralizing antibodies against Omicron BA.2 across vaccine priming subgroups and against Omicron BA.1 (evaluated in BNT162b2-primed participants). Similar patterns in antibody responses were observed for participants aged [≥]56 years. No safety concerns were identified. Conclusion CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing antibodies against multiple variants, regardless of priming vaccine. ClinicalTrials.gov: NCT04762680
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial

Chijioke Bennett,E Joy Rivers,Wayne Woo,Mark Bloch,King Cheung,Paul Griffin,Rahul Mohan,Sachin Deshmukh,Mark Arya,Oscar Cumming,A Munro Neville,Toni McCallum Pardey,Joyce S Plested,Shane Cloney-Clark,Mingzhu Zhu,Raj Kalkeri,Nita Patel,Agi Buchanan,Alex Marcheschi,Jennifer Swan,Gale Smith,Iksung Cho,Gregory M Glenn,Robert Walker,Raburn M Mallory

DOI: https://doi.org/10.1093/infdis/jiad508

2024-07-25

Abstract:Background: Mutations present in emerging SARS-CoV-2 variants permit evasion of neutralization with prototype vaccines. A novel Omicron BA.1 subvariant-specific vaccine (NVX-CoV2515) was tested alone or as a bivalent preparation with the prototype vaccine (NVX-CoV2373) to assess antibody responses to SARS-CoV-2. Methods: Participants aged 18 to 64 years immunized with 3 doses of prototype mRNA vaccines were randomized 1:1:1 to receive a single dose of NVX-CoV2515, NVX-CoV2373, or the bivalent mixture in a phase 3 study investigating heterologous boosting with SARS-CoV-2 recombinant spike protein vaccines. Immunogenicity was measured 14 and 28 days after vaccination for the SARS-CoV-2 Omicron BA.1 sublineage and ancestral strain. Safety profiles of vaccines were assessed. Results: Of participants who received trial vaccine (N = 829), those administered NVX-CoV2515 (n = 286) demonstrated a superior neutralizing antibody response to BA.1 vs NVX-CoV2373 (n = 274) at day 14 (geometric mean titer ratio, 1.6; 95% CI, 1.33-2.03). Seroresponse rates were 73.4% (91/124; 95% CI, 64.7-80.9) for NVX-CoV2515 vs 50.9% (59/116; 95% CI, 41.4-60.3) for NVX-CoV2373. All formulations were similarly well tolerated. Conclusions: NVX-CoV2515 elicited a superior neutralizing antibody response against the Omicron BA.1 subvariant as compared with NVX-CoV2373 when administered as a fourth dose. Safety data were consistent with the established safety profile of NVX-CoV2373. Clinical trials registration: ClinicalTrials.gov (NCT05372588).

Combinatorial Auction Based Mechanism Design for Course Offering Determination

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

The activity and toxicity of ampules amytal sodium and seconal sodium in aqueous polyethylene glycol 200.

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Immunogenicity, clinical efficacy and safety of additional second COVID‐19 booster vaccines against Omicron and its subvariants: A systematic review

Indications for surgical intervention in middle cerebral artery obstruction.

Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines

Getting men to talk about suicide.

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines

Single equivalent dipole inverse electrocardiography based on ordinary 12 leads recordings

Safety and Immunogenicity of an mRNA-1273 Booster in Children

Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial